EP0736087A1 - Monoklonale antikoerper gegen hev orf-2 und verfahren zur deren verwendung - Google Patents
Monoklonale antikoerper gegen hev orf-2 und verfahren zur deren verwendungInfo
- Publication number
- EP0736087A1 EP0736087A1 EP95905967A EP95905967A EP0736087A1 EP 0736087 A1 EP0736087 A1 EP 0736087A1 EP 95905967 A EP95905967 A EP 95905967A EP 95905967 A EP95905967 A EP 95905967A EP 0736087 A1 EP0736087 A1 EP 0736087A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hev
- monoclonal antibody
- antibody
- orf
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 title claims abstract description 32
- 239000000427 antigen Substances 0.000 claims abstract description 60
- 102000036639 antigens Human genes 0.000 claims abstract description 60
- 108091007433 antigens Proteins 0.000 claims abstract description 60
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 13
- 238000003149 assay kit Methods 0.000 claims abstract description 4
- 239000007790 solid phase Substances 0.000 claims description 54
- 238000012360 testing method Methods 0.000 claims description 40
- 239000003153 chemical reaction reagent Substances 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 27
- 210000004027 cell Anatomy 0.000 claims description 16
- 238000009739 binding Methods 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 13
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000003018 immunoassay Methods 0.000 claims description 8
- 238000012875 competitive assay Methods 0.000 claims description 6
- 230000009467 reduction Effects 0.000 claims description 5
- 230000002285 radioactive effect Effects 0.000 claims description 2
- 241000724675 Hepatitis E virus Species 0.000 abstract description 94
- 239000000523 sample Substances 0.000 description 29
- 239000011324 bead Substances 0.000 description 25
- 108010013746 3-deoxy-manno-octulosonate cytidyltransferase Proteins 0.000 description 18
- 238000003556 assay Methods 0.000 description 18
- 230000009870 specific binding Effects 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 9
- -1 polyethylene Polymers 0.000 description 9
- 210000004988 splenocyte Anatomy 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 8
- 150000001413 amino acids Chemical group 0.000 description 8
- 238000002820 assay format Methods 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000003053 immunization Effects 0.000 description 8
- 239000011859 microparticle Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 241000283707 Capra Species 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 108700026244 Open Reading Frames Proteins 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000037865 fusion proteins Human genes 0.000 description 4
- 108020001507 fusion proteins Proteins 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000004621 scanning probe microscopy Methods 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 239000012491 analyte Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 229920000126 latex Polymers 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 241000276498 Pollachius virens Species 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 229920002113 octoxynol Polymers 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 230000002516 postimmunization Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 150000003573 thiols Chemical group 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 1
- UUEWCQRISZBELL-UHFFFAOYSA-N 3-trimethoxysilylpropane-1-thiol Chemical compound CO[Si](OC)(OC)CCCS UUEWCQRISZBELL-UHFFFAOYSA-N 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 240000005020 Acaciella glauca Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 244000007835 Cyamopsis tetragonoloba Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002319 Poly(methyl acrylate) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229910021536 Zeolite Inorganic materials 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940064734 aminobenzoate Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000001745 anti-biotin effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- HNPSIPDUKPIQMN-UHFFFAOYSA-N dioxosilane;oxo(oxoalumanyloxy)alumane Chemical compound O=[Si]=O.O=[Al]O[Al]=O HNPSIPDUKPIQMN-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- FWDBOZPQNFPOLF-UHFFFAOYSA-N ethenyl(triethoxy)silane Chemical compound CCO[Si](OCC)(OCC)C=C FWDBOZPQNFPOLF-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002985 plastic film Substances 0.000 description 1
- 229920006255 plastic film Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000193 polymethacrylate Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000135 prohibitive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001799 protein solubilization Methods 0.000 description 1
- 230000007925 protein solubilization Effects 0.000 description 1
- 235000003499 redwood Nutrition 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000004574 scanning tunneling microscopy Methods 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 150000004756 silanes Chemical class 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Chemical class [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000002764 solid phase assay Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 239000003656 tris buffered saline Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000010457 zeolite Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- This invention relates generally to antibodies which specifically bind to
- HEV Hepatitis E Virus
- HEV orf-2 antigen a novel hybridoma cell line which secretes monoclonal antibodies to HEV orf-2 antigen, and methods for using these monoclonal antibodies.
- HEV variously referred to as waterborne, epidemic or enterically l o transmitted non-A, non-B hepatitis (ET-NANBH)
- ET-NANBH enterically l o transmitted non-A, non-B hepatitis
- HEV genome has been cloned and expressed in E. coli as fusion proteins with glutathione-S-transferase (GST). See, for example, S. 5 J. Skidmore et al., supra.
- GST glutathione-S-transferase
- B Burmese
- M Mexican strain
- the two antigens from the Mexican strain correspond to l o amino acid sequences at the carboxy-terminus of the second open reading frame (ORF-2) and the third open reading frame (orf-2), respectively.
- the two antigens from the Burmese strain, B 3-2 and B 4-2, correspond to amino acid sequences at the carboxy-terminus of orf-2 and orf-2, respectively.
- the M 3-2 and B 3-2 recombinant antigens both comprise 42 amino acids from the carboxy terminus of
- the degree of amino acid homology between these sequences of 42 amino acids is 90.5%.
- the M 4-2 and B 4-2 recombinant antigens each comprise 33 amino acids from the carboxy terminus of orf-2; the degree of homology between these two sequences of 33 amino acids is 73.5%. Id.
- Tests developed for detection of HEV must contain reagents which are
- the present invention provides a highly specific and novel monoclonal antibody or fragment thereof that can be employed for the detection of HEV orf-2 antigen.
- the monoclonal antibody specifically binds to the HEV orf-2 protein.
- the hybridoma which secretes the monoclonal antibody is identified as: Hybridoma cell line H1C119 (A.T.C.C. deposit No. HB11521, secreting monoclonal antibody (H1C119).
- H1C119 secreting monoclonal antibody
- the monoclonal antibody of the present invention can be used in an immunoassay for the detection of HEV antigen or antibody.
- Many such immunoassay formats are known in the art and can be modified by adding a known amount of a monoclonal antibody which specifically binds to HEV orf-2 antigen.
- a particularly preferred assay format is a competitive assay for determining the presence and amount of HEV antibody which may be present in a test sample.
- the assay involves contacting a test sample suspected of containing HEV antibodies with a solid phase coated with HEV antigens and an indicator reagent comprising a signal generating compound and a monoclonal antibody which specifically binds to HEV orf-2 antigen, for a time and under conditions sufficient to form antigen/antibody complexes of the test sample and solid phase and/or indicator reagent and solid phase; and determining the presence of HEV antibody present in the test sample by detecting the reduction in binding of the indicator reagent to the solid phase as compared to the signal generated from a negative test sample to indicate the presence of HEV antibody in the test sample
- Figure 1 is a schematic representation of the plasmid used for production of orf-2 CKS/HEV SG-2 antigen from plasmids pJO201 and pGEX-HEV-ORF2- SG-3.
- the monoclonal antibody of the present invention can be employed in various assay systems to determine the presence, if any, of HEV antigens or HEV antibodies in a test sample. Fragments of the monoclonal antibody provided also may be used.
- the monoclonal antibody of the present invention may be screened for as follows.
- Recombinant or synthetic HEV orf-2 antigen is used on a solid phase 5 (preferably, polystyrene beads).
- CKS CMP-KDO synthetase
- SG-3 CMP-KDO synthetase
- EIA immunoassay which uses the synthetic peptide spB3-2 (obtained as described in copending application U.S. Serial Number 08/089,877 l o filed July 9, 1993) on the solid phase is utilized.
- Detection of non-specific binding is accomplished by coating the solid phase with CKS alone or with a non-HEV CKS recombinant protein.
- Test samples (mouse serum, tissue culture supernatant, or mouse ascites fluid) are serially diluted in a specimen diluent and a portion is incubated with each solid phase for 1-2 hours at 40°C. Beads are then
- the monoclonal antibody of the invention can be employed as a competitive probe for the detection of antibodies to HEV antigen.
- HEV antigens coated on a solid phase are contacted
- a polyclonal or monoclonal anti-HEV antibody or a fragment thereof, which has been coated on a solid phase is contacted with a test sample which may contain HEV antigens, to form a mixture.
- a test sample which may contain HEV antigens
- This mixture is incubated for a time and under conditions sufficient to form antigen/antibody complexes.
- an indicator reagent comprising a monoclonal or a polyclonal antibody or a fragment thereof, which specifically binds to HEV antigen, to which a signal generating compound which generates a measurable signal has been attached, is contacted with the
- HEV antigen/antibody complexes to form a second mixture.
- This second mixture then is incubated for a time and under conditions sufficient to form antibody/antigen/indicator reagent complexes.
- the presence of HEV antigen present in the test sample and captured on the solid phase, if any, is determined by detecting the measurable signal generated by the signal generating compound.
- the l o amount of HEV antigen present in the test sample is proportional to the signal generated.
- a polyclonal or monoclonal anti-HEV antibody or fragment thereof which is bound to a solid support, the test sample and an indicator reagent comprising a monoclonal or polyclonal antibody or fragments thereof, which
- HEV antigen 15 specifically binds to HEV antigen to which a signal generating compound which generates a measurable signal is attached, are contacted simultaneously to form a mixture. This mixture is incubated for a time and under conditions sufficient to form antibody/antigen/indicator reagent complexes. The presence, if any, of HEV antigen present in the test sample and captured on the solid phase is determined by
- the monoclonal antibody of the invention can be employed either as the capture phase or as part of the indicator reagent.
- the monoclonal antibody of the present invention can be employed in the detection of HEV antigen in fixed tissue sections, as well as fixed cells by immunohistochemical analysis, by standard methods well- known to those skilled in the art.
- the monoclonal antibody can be bound to matrices similar to
- the monoclonal antibody of the invention also can be used for the generation of chimeric antibodies for therapeutic use, or other similar applications.
- the monoclonal antibody or fragment thereof can be provided individually
- Combinations of the monoclonal antibody (and fragments thereof) of the present invention provided herein also may be used in combination with other monoclonal antibodies that have differing specificities for HEV as components in a mixture or "cocktail" of HEV antibodies, each having different binding specificities.
- this cocktail can include the monoclonal antibody of the invention directed to orf-2 protein from the HEV genome, along with different monoclonal antibodies directed to other HEV regions, such as the orf-3 HEV protein or other binding sites on orf-2 HEV protein.
- This cocktail of monoclonal 5 antibodies would then be used in place of the single monoclonal antibody as described in the assay formats herein.
- the polyclonal antibody or fragment thereof which can be used in the assay formats should specifically bind to HEV antigen.
- the polyclonal antibody used preferably is of mammalian origin and includes but is not limited to human, l o goat, rabbit or sheep anti-HEV polyclonal antibody.
- the polyclonal antibodies used in the assays can be used either alone or as a cocktail of polyclonal antibodies. Since the cocktails used in the assay formats are comprised of either monoclonal antibodies or polyclonal antibodies having different HEV specificity, they would be useful for diagnosis, evaluation and prognosis of HEV infection, as
- Test samples which can be tested by the methods of the present invention described herein include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, biological fluids such as cell culture supernatants, fixed tissue specimens and fixed cell specimens.
- the "solid phase” is not critical and can be selected by one skilled in the art.
- latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips and tanned sheep red blood cells are all suitable examples.
- Suitable methods for immobilizing peptides on solid phases include ionic, hydrophobic, covalent
- a “solid phase”, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction.
- the solid phase can be chosen for its intrinsic ability to attract and immobilize the capture reagent.
- the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent.
- the additional receptor 0 can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent.
- the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid phase and which has the ability to immobilize the capture reagent through a specific binding reaction.
- 35 receptor molecule enables the indirect binding of the capture reagent to a solid phase material before the performance of the assay or during the performance of the assay.
- the solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, and other configurations known to those of ordinary skill in the art.
- the solid phase also can comprise any suitable porous material with sufficient porosity to allow 5 access by detection antibodies and a suitable surface affinity to bind antigens.
- Microporous structures are generally preferred, but materials with gel structure in the hydrated state may be used as well.
- Such useful solid supports include: natural polymeric carbohydrates and their synthetically modified, cross- linked or substituted derivatives, such as agar, agarose, cross-linked alginic acid, l o substituted and cross-linked guar gums, cellulose esters, especially with nitric acid and carboxylic acids, mixed cellulose esters, and cellulose ethers; natural polymers containing nitrogen, such as proteins and derivatives, including cross-linked or modified gelatins; natural hydrocarbon polymers, such as latex and rubber; synthetic polymers which may be prepared with suitably porous structures, such
- vinyl polymers including polyethylene, polypropylene, polystyrene, polyvinylchloride, polyvinylacetate and its partially hydrolyzed derivatives, polyacrylamides, polymethacrylates, copolymers and terpolymers of the above polycondensates, such as polyesters, polyamides, and other polymers, such as polyurethanes or polyepoxides; porous inorganic materials such as sulfates or
- alkaline earth metals and magnesium including barium sulfate, calcium sulfate, calcium carbonate, silicates of alkali and alkaline earth metals, aluminum and magnesium; and aluminum or silicon oxides or hydrates, such as clays, alumina, talc, kaolin, zeolite, silica gel, or glass (these materials may be used as filters with the above polymeric materials); and mixtures or copolymers of
- graft copolymers obtained by initializing polymerization of synthetic polymers on a pre-existing natural polymer. All of these materials may be used in suitable shapes, such as films, sheets, or plates, or they may be coated onto or bonded or laminated to appropriate inert carriers, such as paper, glass, plastic films, or fabrics.
- the porous structure of nitrocellulose has excellent absorption and adsorption qualities for a wide variety of reagents including monoclonal antibodies.
- Nylon also possesses similar characteristics and also is suitable.
- porous solid supports described hereinabove are preferably in the form of sheets of thickness from about 0.01 to 0.5 mm,
- the pore size may vary within wide limits, and is preferably from about 0.025 to 15 microns, especially from about 0.15 to 15 microns.
- a charged substance can be coated directly to the material or onto microparticles which then are retained by a solid phase support material.
- microparticles can serve as the solid phase, by being retained in a column or being suspended in the 5 mixture of soluble reagents and test sample, or the particles themselves can be retained and immobilized by a solid phase support material.
- retained and immobilized is meant that the particles on or in the support material are not capable of substantial movement to positions elsewhere within the support material.
- the particles can be selected by one skilled in the art from any suitable l o type of particulate material and include those composed of polystyrene, polymethylacrylate, polypropylene, latex, polytetrafluoroethylene, polyacrylonitrile, polycarbonate, or similar materials.
- the size of the particles is not critical, although it is preferred that the average diameter of the particles be smaller than the average pore size of the support material being used.
- the methods of the present invention can be adapted for use in systems which utilize microparticle technology including automated and semi-
- the indicator reagent comprises a signal generating compound (label) which is capable of generating a measurable signal detectable by external means conjugated (attached) to a specific binding member for HEV.
- label a signal generating compound
- Specific binding member means a member of a specific binding pair. That is, two different molecules where one of the molecules through chemical or physical means specifically binds to the second molecule.
- the indicator reagent also can be a member of any specific binding pair, including either hapten-anti-hapten systems 5 such as biotin or anti-biotin, avidin or biotin, a carbohydrate or a lectin, a complementary nucleotide sequence, an effector or a receptor molecule, an enzyme cofactor and an enzyme, an enzyme inhibitor or an enzyme, and the like.
- An immunoreactive specific binding member can be an antibody, an antigen, or an antibody/antigen complex that is capable of binding either to HEV as in a sandwich l o assay, to the capture reagent as in a competitive assay, or to the ancillary specific binding member as in an indirect assay.
- the various signal generating compounds (labels) contemplated include chromogens, catalysts such as enzymes, luminescent compounds such as fluorescein and rhodamine, chemiluminescent compounds, radioactive elements,
- enzymes include alkaline phosphatase, horseradish peroxidase, beta-galactosidase, and the like.
- the selection of a particular label is not critical, but it will be capable of producing a signal either by itself or in conjunction with one or more additional substances.
- An immobilizable immune complex is separated from the rest of the reaction mixture by ionic interactions between the negatively charged poly-anion/immune complex and the previously treated, positively charged porous matrix and detected by using
- the methods of the present invention can be adapted for use in systems which utilize microparticle technology including in automated and semi- automated systems wherein the solid phase comprises a microparticle.
- Such systems include those described in pending U. S. Patent Applications 425,651 and 425,643, which correspond to published EPO applications Nos. EP 0425 633 and EP 0424 634, respectively, which are incorporated herein by reference.
- SPM scanning probe microscopy
- the capture phase for example, at least one of the monoclonal antibodies of the invention
- a scanning probe microscope is utilized to detect antigen/antibody complexes which may be present on the surface of the solid phase.
- the use of scanning tunneling microscopy l o eliminates the need for labels which normally must be utilized in many immunoassay systems to detect antigen/antibody complexes. Such a system is described in pending U. S. patent application Serial No. 662,147, which enjoys common ownership and is incorporated herein by reference.
- one member of a specific binding partner is attached to a surface suitable for scanning.
- the attachment of the analyte specific substance may be by adsorption to a test piece which comprises a solid phase of a plastic or metal surface, following methods known to those of ordinary skill in the art.
- a specific binding partner analyte specific substance
- Covalent attachment methods are known to those skilled in the art and include a variety of means to irreversibly link specific binding partners to the test piece. If the test piece is silicon or glass, the surface must be
- Activated silane compounds such as triethoxy amino propyl silane (available from Sigma Chemical Co., St. Louis, MO), triethoxy vinyl silane (Aldrich Chemical Co., Milwaukee, WI), and (3-mercapto-propyl)-trimethoxy silane (Sigma Chemical Co., St. Louis, MO) can be used to introduce reactive groups such as amino-, vinyl, and thiol,
- Such activated surfaces can be used to link the binding partner directly (in the cases of amino or thiol) or the activated surface can be further reacted with linkers such as glutaraldehyde, bis (succinimidyl) suberate, SPPD 9 succinimidyl 3-[2-pyridyldithio] propionate), SMCC (succinimidyl-4-[N- maleimidomethyl] cyclohexane-1-carboxylate), SLAB (succinimidyl [4-iodoacetyl]
- linkers such as glutaraldehyde, bis (succinimidyl) suberate, SPPD 9 succinimidyl 3-[2-pyridyldithio] propionate), SMCC (succinimidyl-4-[N- maleimidomethyl] cyclohexane-1-carboxylate), SLAB (succinimidyl [4-iodoacet
- the vinyl group can be oxidized to provide a means for covalent attachment. It also can be used as an anchor for the polymerization of various polymers such as poly acrylic acid, which can provide multiple attachment points for specific binding partners.
- the amino surface can be reacted with oxidized dextrans of various molecular weights to provide hydrophilic linkers of different size and capacity.
- oxidizable dextrans examples include Dextran T-40 (molecular weight 40,000 daltons), Dextran T-l 10 (molecular 5 weight 110,000 daltons), Dextran T-500 (molecular weight 500,000 daltons), Dextran T-2M (molecular weight 2,000,000 daltons) (all of which are available from Pharmacia, Piscataway, NJ), or Ficoll (molecular weight 70,000 daltons (available from Sigma Chemical Co., St. Louis, MO). Also, polyelectrolyte interactions may be used to immobilize a specific binding partner on a surface of a l o test piece by using techniques and chemistries described by pending U. S. Patent applications Serial No.
- the surface 15 may be further treated with materials such as serum, proteins, or other blocking agents to minimize non-specific binding.
- the surface also may be scanned either at the site of manufacture or point of use to verify its suitability for assay purposes. The scanning process is not anticipated to alter the specific binding properties of the test piece.
- the monoclonal antibody of the invention can be used as a positive control in an assay which is designed to detect the presence of HEV antibody.
- HEV antigens would be used as a capture phase. These HEV antigens could be prepared by various means from viral lysates, synthetic peptides of various
- the reagent employed for the assay can be provided in the form of a kit with one or more containers such as vials or bottles, with each container containing a separate reagent such as a monoclonal antibody, or a cocktail of monoclonal antibodies, employed in the assay.
- kits also could 5 contain vials or containers of other reagents needed for performing the assay, such as washing, processing and indicator reagents.
- a recombinant DNA clone was constructed to contain the gene encoding the full length orf-2 of HEV as a fusion protein with CKS.
- This antigen (designated SG-3 protein) expressed by this clone was used to immunize a mouse from which an immune splenocyte was fused to a SP2/0-Agl4 myeloma cell to produce a hybridoma cell line that secretes a monoclonal antibody
- immunoglobulin (Ig) class Gi (IgGi) reactive with HEV orf-2.
- the resultant immunoglobulin was produced in mouse ascites fluid and was purified by affinity chromatogr aphy .
- GST glutathione S-transferase
- the CKS/HEV-SG-3 protein was expressed in E. coli strain XL 1 -Blue at greater than 20% of total cell protein after induction with isopropyl b-D thiogalactoside (IPTG).
- IPTG isopropyl b-D thiogalactoside
- the clones were propagated in 10 liter fermentors, yielding 170-260 grams of wet cell paste per fermentation.
- the E. coli cells expressing the SG-3 protein were lysed at pH 10 in the presence of various protease inhibitors.
- the CKS fusion protein was insoluble 5 and remained in the pellet after centrifugation. Pellets were washed with various detergents to remove non-specific proteins. Following solubilization in Tris, pH 8.5 containing 0.5% SDS, the CKS fusion protein was found to represent 50 to 60% of the total protein as evaluated by SDS-PAGE and gel densitometry.
- the solubilized protein was further purified by Sephacryl S-300HR column l o chromatography. Fractions were analyzed by SDS-PAGE, pooled and evaluated for purity by gel densitometry. Final purified protein was greater than 90% pure.
- the immunization regimen (4 mice) consisted of an initial immunization
- mice 15 with additional immunizations at six and nine weeks.
- mice (Balb/c) were inoculated intraperitoneally with this emulsion.
- mouse serum was screened for 0 enzyme immunoassay (EIA) immunoreactivity as described below.
- EIA enzyme immunoassay
- the serum anti-HEV titer tested against beads coated with HEV SG-3 was 2 x 10 ** * in specimen diluent containing E. coli and CKS lysate and 10 3 against beads coated with CKS alone.
- mice Four weeks after the first immunization, three mice were boosted intraperitoneally with 10 ⁇ g of the immunizing protein in incomplete Freund's adjuvant.
- post-immunization anti-HEV titers from boosted mouse No. 4 against beads coated with protein HEV SG-3 described above were 1.5 x 0 l ⁇ 6 in specimen diluent with no additives to block out unwanted reactivity, 2 x 10 ⁇ in specimen diluent with additives and 5.0 x 10 ⁇ against spB3-2.
- This mouse was then boosted intravenously (via the tail vein) with 30 ⁇ g of the immunizing protein and used for fusion 3 days later.
- Normal mouse splenocytes were prepared by aseptically removing the spleen from a non-immunized mouse and crushing it using the plunger of a syringe through a screen that fits into a 60 x 15 mm Petri dish containing a small amount of Dulbecco's' Minimum Essential (DME) medium.
- DME Dulbecco's' Minimum Essential
- the splenocyte solution was washed with DME medium, and the red blood cells were lysed by adding 1 ml of 0.83% NH4CI in lOmM Tris to the cell pellet for 1 minute. The cells were again washed and resuspended in 40 mis of DME medium containing 20% Fetal Bovine Serum (FBS).
- DME Dulbecco's' Minimum Essential
- the immunized mouse was sacrificed, and the spleen was removed and processed as described herein for the preparation of normal splenocytes except that the splenocytes were resuspended in 10 mis DME medium and counted.
- Splenocytes were fused in a 1 : 1 ratio with the SP2/0 myeloma cell line using the described modification of conventional methods
- Hybrid #1 had an optical density (O.D). of 1.155 when tested at a 1: 10 dilution against SG-3 antigen- coated beads and was negative against CKS-only coated beads, and HEV spB3-2 beads. HI was then cloned at one cell per well by limiting dilution technique as described in Goding,
- 96 multiwell tissue culture tray an aliquot containing 100 cells was added to 20 mis of DME media containing 20% Fetal Bovine Serum (FBS) and 5x10 ⁇ normal mouse splenocytes. An eight channel pipetman adjusted to 0.2 ml was used to plant the cell suspension. The trays were incubated at 37°C in a humidified 5% CO2 incubator and refed on days 5 and 7 or as needed because of evaporation.
- FBS Fetal Bovine Serum
- HlCl 19 Monoclonal Antibody Clones selected for further evaluation were scaled up in tissue culture T- flasks and 10" cells were injected into the peritoneal cavity of pre-pristaned BALB/c mice (Charles River Biotechnical Services, Inc., Wilmington, MA) (see Hurrell, supra).
- the resulting ascites fluid was harvested 7-10 days after injection, centrifuged and frozen.
- the antibody was affinity purified on a Protein A Sepharose CL-4B (Pharmacia-LKB Biotechnologies, Piscataway, NJ). Bound monoclonal antibody was eluted from the column at a pH of 5.5, indicating its subtype as IgG] .
- EIA's enzyme immunoassays
- the CKS-HEV recombinant orf-2 (SG-3) (prepared as described in Example 1) was coated on the solid phase in either the unpurified (extracted and solubilized) form (ca. 50-60% pure HEV protein) or a purified protein (>90% pure)
- another EIA used the synthetic peptide spB3-2 on the solid phase, and to detect non-specific binding the solid phase was coated with CKS alone or a non- HEV CKS recombinant protein.
- mouse serum, tissue culture supernatant, mouse ascites fluid samples or monoclonal antibody (MAb) HlCl 19 obtained above were serially diluted 5 to 10-fold in specimen diluent containing phosphate-buff ered- saline/Tris/EDTA, pH 7.8 with 20% goat serum, 10% fetal calf serum, 1% bovine serum albumin, 0.2% Triton-X 100, 0.1% sodium azide, with or without 1% E. coli lysate and 0.01% CKS added, then 200 ⁇ l was incubated with each solid phase for 1-2 hours at 40°C. Beads were then washed 3 times with 5 ml distilled water.
- MAb monoclonal antibody
- Bound antibody was detected using 200 ⁇ l HRPO-labeled second antibody (Goat anti-mouse IgG H+L) from Kirkegaard and Perry Labs) at 0.3 ⁇ g/mL in conjugate diluent containing Tris-buffered-saline with 10% goat serum, 10% fetal calf serum and 0.15% Triton-X 100. Beads were incubated with conjugate for 1 hour at 40°C, and washed as before.
- O-Phenylenediamine (OPD) substrate was freshly prepared by adding 1 OPD tablet (Abbott) per 5 mis of OPD Diluent (Abbott), and 300 ⁇ l of OPD substrate solution was then added to each washed bead and incubated in the dark at room temperature for 30 minutes.
- One ml of sulfuric acid added to stop the reaction, and the amount of color generated was determined by measuring the absorbance of the substrate at 492 nm with 2 hours of sulfuric acid addition. Results given in Table 1 below indicate that the antibody was specific for the orf-2 region of HEV.
- Solid phase was coated with HEV orf-2 (SG-3) or a combination of l o proteins coding for the orf-2 and orf-3 regions.
- the solid phases were pre- incubated with a 1 :2 dilution of HEV negative human plasma (negative control) or human plasma known to contain HEV Ab (sample) in specimen diluent overnight at room temperature. Beads were then washed and monoclonal antibody (MAb) of the invention against HEV orf-2, diluted to give an O.D. of 1.000 - 2.000 when
- the HEV Ab positive sample showed 20.0% inhibition of MAb HlCl 19 when the SG-3 bead was used, and 54.2 % inhibition when the HEV orf-2/orf-3 Combo bead was used.
- the results are given in Table
- Solid phase is coated with HEV orf-2 (SG-3) protein.
- Monoclonal antibody (MAb) HlCl 19 at a concentration previously determined to give an O.D. of 1.000 - 2.000 in this assay format, is pre-incubated with sample at a time l o and temperature long enough to allow binding of HEV antigen in the sample to MAb (30-120 minutes, at room temperature to 40°C).
- the solid phase is then added, and the mixture and bead are incubated at a time and temperature long enough to allow any remaining unbound MAb to bind to the solid phase (temperature range: room temperature to 40°C, time range: 1 - 16 hours). Binding
- MAb 15 of MAb to the solid phase is then detected either using a labeled second antibody (e.g. horseradish peroxidase (HRPO)-labelled Goat anti-mouse IgG) with incubation of 1-2 hours at 40°C, or MAb itself could be labeled, thus making the assay potentially performable in one step.
- a labeled second antibody e.g. horseradish peroxidase (HRPO)-labelled Goat anti-mouse IgG
- HRPO horseradish peroxidase
- HEV antigen containing sample will inhibit the MAb from binding to the solid phase and reduce the signal at least 50%.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17194893A | 1993-12-22 | 1993-12-22 | |
US171948 | 1993-12-22 | ||
PCT/US1994/014505 WO1995017501A1 (en) | 1993-12-22 | 1994-12-16 | Monoclonal antibodies against hev orf-2 and methods for using same |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0736087A1 true EP0736087A1 (de) | 1996-10-09 |
Family
ID=22625753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95905967A Withdrawn EP0736087A1 (de) | 1993-12-22 | 1994-12-16 | Monoklonale antikoerper gegen hev orf-2 und verfahren zur deren verwendung |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0736087A1 (de) |
JP (1) | JPH09507025A (de) |
AU (1) | AU1437695A (de) |
CA (1) | CA2179609A1 (de) |
WO (1) | WO1995017501A1 (de) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6787145B1 (en) | 1992-09-18 | 2004-09-07 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
DE69334299D1 (de) | 1992-09-18 | 2009-12-31 | Us Gov Health & Human Serv | Rekombinante proteine eines pakistani stammes von hepatitis e-virus sowie ihre verwendung in diagnostischen verfahren und als vakzine |
US6207416B1 (en) | 1992-09-18 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
KR100359526B1 (ko) * | 1994-10-03 | 2003-02-25 | 더 가브먼트 오브 더 유나이티드 스테이츠 오브 아메리카, 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | E형간염파키스탄형균주의재조합단백질및이를이용한진단방법과백신 |
US6054567A (en) * | 1997-04-11 | 2000-04-25 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
US6458562B1 (en) | 1998-04-09 | 2002-10-01 | The United States Of America As Represented By The Secretary Of Health And Human Services | Recombinant proteins of a Pakistani strain of hepatitis E and their use in diagnostic methods and vaccines |
CN101367869B (zh) * | 2000-09-30 | 2012-12-05 | 北京万泰生物药业股份有限公司 | 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗 |
EP1452541B2 (de) * | 2001-11-08 | 2015-06-17 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Monoklonale antikörper gegen das hepatitis-e-virus, bindende fragemente davon und deren verwendung |
WO2023174976A1 (en) | 2022-03-16 | 2023-09-21 | Universität Zu Lübeck | Broadly neutralizing antibodies against hepatitis e virus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU632271B2 (en) * | 1988-03-30 | 1992-12-24 | Abbott Laboratories | Production of monoclonal antibodies specific for non-a, non-b hepatitis infected liver |
US6455492B1 (en) * | 1988-06-17 | 2002-09-24 | Genelabs Technologies, Inc. | Hepatitis E virus vaccine and method |
US5885768A (en) * | 1988-06-17 | 1999-03-23 | The United States Of America As Represented By The Department Of Health And Human Services | Hepatitis E virus peptide antigen and antibodies |
-
1994
- 1994-12-16 EP EP95905967A patent/EP0736087A1/de not_active Withdrawn
- 1994-12-16 JP JP7517515A patent/JPH09507025A/ja active Pending
- 1994-12-16 CA CA002179609A patent/CA2179609A1/en not_active Abandoned
- 1994-12-16 WO PCT/US1994/014505 patent/WO1995017501A1/en not_active Application Discontinuation
- 1994-12-16 AU AU14376/95A patent/AU1437695A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
See references of WO9517501A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1995017501A1 (en) | 1995-06-29 |
AU1437695A (en) | 1995-07-10 |
JPH09507025A (ja) | 1997-07-15 |
CA2179609A1 (en) | 1995-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5308750A (en) | Monoclonal antibodies to putative HCV E2/NS1 proteins and methods for using same | |
US5854001A (en) | Hepatitis C virus fusion proteins | |
US4716104A (en) | Detecting presence of HCMV-specific IgM | |
US8541188B2 (en) | Differential immunoassay for PRRS vaccine antibody | |
US5256561A (en) | Monoclonal antibody to HIV-2 and uses thereof | |
KR100730529B1 (ko) | Hcv 코어 항원의 검출 또는 정량 방법 및 이에사용하기 위한 검출 또는 정량용 시약 | |
WO1995017501A1 (en) | Monoclonal antibodies against hev orf-2 and methods for using same | |
JP3506252B2 (ja) | Htlv−i/htlv−iiの分析及び方法 | |
US5830636A (en) | HEV orf-2 monoclonal antibodies and methods for using same | |
US5667966A (en) | Mouse monoclonal antibodies to Hepatitis E virus and methods for using same | |
US10634676B2 (en) | Method and kit for simultaneously detecting human parvovirus B19 antigen and antibody | |
EP0599913B1 (de) | Monoklonale antikörper gegen mutmassliche hepatitis c-virus ns5-proteine und ihre anwendungsmethoden | |
WO1995002070A1 (en) | Confirmatory assay and reagents for hepatitis e virus | |
RU2329303C2 (ru) | Моноклональное антитело, иммунореактивное с белком нуклеокапсида (кор) вируса гепатита с-4g5, способ диагностики вгс-инфекции и комбинация моноклональных антител для его осуществления | |
WO2000004383A2 (en) | Hiv group o positive control |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19960619 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE ES FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 20010212 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20010823 |